Some British myeloma specialists are holding back information about costly new treatments that may be difficult to obtain through the National Health Service to avoid distressing patients, according to a poll from Myeloma UK. The charity's survey came after the National Institute for Health and Clinical Excellence deemed four kidney cancer treatments too expensive for NHS use.

Related Summaries